CN103550517B - 一种治疗肝癌的药物 - Google Patents
一种治疗肝癌的药物 Download PDFInfo
- Publication number
- CN103550517B CN103550517B CN201310531322.4A CN201310531322A CN103550517B CN 103550517 B CN103550517 B CN 103550517B CN 201310531322 A CN201310531322 A CN 201310531322A CN 103550517 B CN103550517 B CN 103550517B
- Authority
- CN
- China
- Prior art keywords
- radix
- herba
- fructus
- blood
- heat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 13
- 206010073071 Hepatocellular carcinoma Diseases 0.000 title claims abstract description 12
- 241000208340 Araliaceae Species 0.000 claims abstract description 5
- 241000255791 Bombyx Species 0.000 claims abstract description 5
- 241000756943 Codonopsis Species 0.000 claims abstract description 5
- 241000222336 Ganoderma Species 0.000 claims abstract description 5
- 239000009636 Huang Qi Substances 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 210000002826 Placenta Anatomy 0.000 claims abstract description 5
- 241001250596 Pleione Species 0.000 claims abstract description 5
- 241000222640 Polyporus Species 0.000 claims abstract description 5
- 239000010135 fructus aurantii immaturus Substances 0.000 claims abstract description 5
- 239000009969 fructus bruceae Substances 0.000 claims abstract description 5
- 235000005035 ginseng Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drugs Drugs 0.000 claims description 4
- 210000004369 Blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 32
- 210000003734 Kidney Anatomy 0.000 abstract description 19
- 231100000614 Poison Toxicity 0.000 abstract description 18
- 230000001737 promoting Effects 0.000 abstract description 14
- 239000003440 toxic substance Substances 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract 1
- 210000004185 Liver Anatomy 0.000 description 30
- 235000009508 confectionery Nutrition 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 210000004072 Lung Anatomy 0.000 description 14
- 206010007247 Carbuncle Diseases 0.000 description 11
- 210000000952 Spleen Anatomy 0.000 description 11
- 230000035922 thirst Effects 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 230000002440 hepatic Effects 0.000 description 7
- 230000025627 positive regulation of urine volume Effects 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 208000001848 Dysentery Diseases 0.000 description 6
- 210000000232 Gallbladder Anatomy 0.000 description 6
- 206010023126 Jaundice Diseases 0.000 description 6
- 208000008425 Protein Deficiency Diseases 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000002522 swelling Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 208000002173 Dizziness Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 206010022114 Injury Diseases 0.000 description 5
- 206010040872 Skin infection Diseases 0.000 description 5
- 210000002784 Stomach Anatomy 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010003549 Asthenia Diseases 0.000 description 4
- 210000001124 Body Fluids Anatomy 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 210000002216 Heart Anatomy 0.000 description 4
- 210000001624 Hip Anatomy 0.000 description 4
- 210000000214 Mouth Anatomy 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 210000004915 Pus Anatomy 0.000 description 4
- 201000000736 amenorrhea Diseases 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000005679 Eczema Diseases 0.000 description 3
- 208000001780 Epistaxis Diseases 0.000 description 3
- 210000003026 Hypopharynx Anatomy 0.000 description 3
- 206010022437 Insomnia Diseases 0.000 description 3
- 210000003127 Knee Anatomy 0.000 description 3
- 206010027327 Menstrual disease Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 231100000611 Venom Toxicity 0.000 description 3
- 210000001048 Venoms Anatomy 0.000 description 3
- 230000003187 abdominal Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000004624 dermatitis Diseases 0.000 description 3
- 231100001003 eczema Toxicity 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000001047 pyretic Effects 0.000 description 3
- 230000000268 renotropic Effects 0.000 description 3
- 230000002269 spontaneous Effects 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 239000002435 venom Substances 0.000 description 3
- 230000002087 whitening Effects 0.000 description 3
- 210000001015 Abdomen Anatomy 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000668709 Dipterocarpus costatus Species 0.000 description 2
- 206010013990 Dysuria Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010018830 Haematemesis Diseases 0.000 description 2
- 208000002672 Hepatitis B Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 206010029410 Night sweats Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 210000003516 Pericardium Anatomy 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037844 Rash Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 210000003932 Urinary Bladder Anatomy 0.000 description 2
- 206010052769 Vertigos Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000003203 everyday Effects 0.000 description 2
- 230000003419 expectorant Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000002349 favourable Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 244000052769 pathogens Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010007625 Cardiogenic shock Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241001517488 Clavus Species 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 240000000773 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000001786 Gonorrhea Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018836 Haematochezia Diseases 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 208000006750 Hematuria Diseases 0.000 description 1
- 208000002287 Hemorrhoids Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000004396 Mastitis Diseases 0.000 description 1
- 206010028334 Muscle spasms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010072736 Rheumatic disease Diseases 0.000 description 1
- 208000005687 Scabies Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010044008 Tonsillitis Diseases 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 206010050040 VIIth nerve paralysis Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010063840 Visceroptosis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000001914 calming Effects 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='300px' height='300px' viewBox='0 0 300 300'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='300.0' height='300.0' x='0.0' y='0.0'> </rect>
<path class='bond-0 atom-1 atom-0' d='M 109.6,162.3 L 122.3,160.9 L 121.2,157.1 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0 atom-1 atom-0' d='M 122.3,160.9 L 132.9,152.0 L 134.9,159.4 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity:1;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0 atom-1 atom-0' d='M 122.3,160.9 L 121.2,157.1 L 132.9,152.0 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity:1;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-13 atom-0 atom-14' d='M 158.0,163.2 L 166.2,171.3' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13 atom-0 atom-14' d='M 166.2,171.3 L 174.4,179.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 109.6,162.3 L 99.7,199.7' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-21 atom-9 atom-1' d='M 82.2,135.0 L 109.6,162.3' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2 atom-2 atom-3' d='M 99.7,199.7 L 62.4,209.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3 atom-3 atom-4' d='M 62.4,209.8 L 23.7,207.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23 atom-7 atom-3' d='M 70.1,189.6 L 66.2,199.7' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23 atom-7 atom-3' d='M 66.2,199.7 L 62.4,209.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-24 atom-3 atom-22' d='M 62.4,209.8 L 72.4,232.2 L 78.9,227.9 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-4 atom-4 atom-5' d='M 23.7,207.8 L 13.6,170.5' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5 atom-5 atom-6' d='M 13.6,170.5 L 46.0,149.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 46.0,149.4 L 55.3,156.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 55.3,156.8 L 64.5,164.3' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8 atom-6 atom-9' d='M 46.0,149.4 L 82.2,135.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-25 atom-6 atom-23' d='M 46.0,149.4 L 51.0,127.4 L 43.3,127.0 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-7 atom-7 atom-8' d='M 88.0,167.0 L 91.1,165.3' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-7 atom-8' d='M 91.1,165.3 L 94.1,163.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9 atom-9 atom-10' d='M 82.2,135.0 L 95.8,98.6 L 88.4,96.6 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-10 atom-10 atom-11' d='M 94.8,94.9 L 86.7,86.7' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 86.7,86.7 L 78.5,78.6' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 89.4,100.4 L 81.2,92.2' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 81.2,92.2 L 73.0,84.1' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 92.1,97.6 L 104.2,94.3' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 104.2,94.3 L 116.4,91.0' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12 atom-12 atom-13' d='M 132.9,74.4 L 136.1,62.3' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12 atom-12 atom-13' d='M 136.1,62.3 L 139.3,50.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 170.6,178.4 L 167.4,190.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 167.4,190.6 L 164.2,202.7' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 178.1,180.4 L 174.9,192.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 174.9,192.6 L 171.7,204.7' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15 atom-14 atom-16' d='M 174.4,179.4 L 211.7,169.3' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16 atom-16 atom-17' d='M 211.7,169.3 L 239.1,196.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16 atom-16 atom-17' d='M 221.3,167.9 L 240.5,187.0' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-22 atom-21 atom-16' d='M 221.6,131.9 L 211.7,169.3' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17 atom-17 atom-18' d='M 239.1,196.6 L 276.5,186.5' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18 atom-18 atom-19' d='M 276.5,186.5 L 286.4,149.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18 atom-18 atom-19' d='M 270.5,178.9 L 277.4,152.7' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-19 atom-19 atom-20' d='M 286.4,149.1 L 258.9,121.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20 atom-20 atom-21' d='M 258.9,121.8 L 221.6,131.9' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20 atom-20 atom-21' d='M 255.4,130.8 L 229.2,137.9' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:2.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text x='142.3' y='159.9' class='atom-0' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='71.5' y='181.4' class='atom-7' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#4284F4' >N</text>
<text x='60.0' y='78.1' class='atom-11' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='124.8' y='95.2' class='atom-12' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='159.8' y='224.6' class='atom-15' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='78.9' y='249.9' class='atom-22' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#3B4143' >H</text>
<text x='43.3' y='118.5' class='atom-23' style='font-size:15px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#3B4143' >H</text>
</svg>
 data:image/svg+xml;base64,<?xml version='1.0' encoding='iso-8859-1'?>
<svg version='1.1' baseProfile='full'
              xmlns='http://www.w3.org/2000/svg'
                      xmlns:rdkit='http://www.rdkit.org/xml'
                      xmlns:xlink='http://www.w3.org/1999/xlink'
                  xml:space='preserve'
width='85px' height='85px' viewBox='0 0 85 85'>
<!-- END OF HEADER -->
<rect style='opacity:1.0;fill:#FFFFFF;stroke:none' width='85.0' height='85.0' x='0.0' y='0.0'> </rect>
<path class='bond-0 atom-1 atom-0' d='M 30.6,45.2 L 35.0,44.6 L 34.7,43.5 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0 atom-1 atom-0' d='M 35.0,44.6 L 38.8,41.8 L 39.3,44.0 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity:1;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-0 atom-1 atom-0' d='M 35.0,44.6 L 34.7,43.5 L 38.8,41.8 Z' style='fill:#E84235;fill-rule:evenodd;fill-opacity:1;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-13 atom-0 atom-14' d='M 43.2,44.4 L 46.1,47.2' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-13 atom-0 atom-14' d='M 46.1,47.2 L 48.9,50.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-1 atom-1 atom-2' d='M 30.6,45.2 L 27.8,55.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-21 atom-9 atom-1' d='M 22.8,37.5 L 30.6,45.2' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-2 atom-2 atom-3' d='M 27.8,55.8 L 17.2,58.7' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-3 atom-3 atom-4' d='M 17.2,58.7 L 6.2,58.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23 atom-7 atom-3' d='M 19.8,51.7 L 18.5,55.2' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-23 atom-7 atom-3' d='M 18.5,55.2 L 17.2,58.7' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-24 atom-3 atom-22' d='M 17.2,58.7 L 20.9,66.4 L 22.7,65.2 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-4 atom-4 atom-5' d='M 6.2,58.1 L 3.4,47.5' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-5 atom-5 atom-6' d='M 3.4,47.5 L 12.5,41.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 12.5,41.6 L 15.8,44.2' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-6 atom-6 atom-7' d='M 15.8,44.2 L 19.0,46.8' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-8 atom-6 atom-9' d='M 12.5,41.6 L 22.8,37.5' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-25 atom-6 atom-23' d='M 12.5,41.6 L 14.0,33.9 L 11.8,33.8 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-7 atom-7 atom-8' d='M 23.0,47.3 L 24.6,46.5' style='fill:none;fill-rule:evenodd;stroke:#4284F4;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-7 atom-7 atom-8' d='M 24.6,46.5 L 26.2,45.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-9 atom-9 atom-10' d='M 22.8,37.5 L 26.7,27.2 L 24.5,26.6 Z' style='fill:#3B4143;fill-rule:evenodd;fill-opacity:1;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1;' />
<path class='bond-10 atom-10 atom-11' d='M 26.4,26.1 L 23.5,23.3' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 23.5,23.3 L 20.7,20.4' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 24.8,27.7 L 22.0,24.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-10 atom-10 atom-11' d='M 22.0,24.8 L 19.1,22.0' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 25.6,26.9 L 29.8,25.7' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-11 atom-10 atom-12' d='M 29.8,25.7 L 34.1,24.6' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12 atom-12 atom-13' d='M 36.7,22.0 L 37.9,17.7' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-12 atom-12 atom-13' d='M 37.9,17.7 L 39.0,13.4' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 47.8,49.8 L 46.7,54.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 46.7,54.1 L 45.6,58.3' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 50.0,50.4 L 48.8,54.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-14 atom-14 atom-15' d='M 48.8,54.6 L 47.7,58.9' style='fill:none;fill-rule:evenodd;stroke:#E84235;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-15 atom-14 atom-16' d='M 48.9,50.1 L 59.5,47.2' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16 atom-16 atom-17' d='M 59.5,47.2 L 67.3,54.9' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-16 atom-16 atom-17' d='M 62.2,46.8 L 67.6,52.2' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-22 atom-21 atom-16' d='M 62.3,36.6 L 59.5,47.2' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-17 atom-17 atom-18' d='M 67.3,54.9 L 77.8,52.1' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18 atom-18 atom-19' d='M 77.8,52.1 L 80.6,41.5' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-18 atom-18 atom-19' d='M 76.1,49.9 L 78.1,42.5' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-19 atom-19 atom-20' d='M 80.6,41.5 L 72.9,33.8' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20 atom-20 atom-21' d='M 72.9,33.8 L 62.3,36.6' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<path class='bond-20 atom-20 atom-21' d='M 71.9,36.3 L 64.4,38.3' style='fill:none;fill-rule:evenodd;stroke:#3B4143;stroke-width:1.0px;stroke-linecap:butt;stroke-linejoin:miter;stroke-opacity:1' />
<text x='39.3' y='45.3' class='atom-0' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='19.3' y='51.4' class='atom-7' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#4284F4' >N</text>
<text x='16.0' y='22.2' class='atom-11' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='34.4' y='27.0' class='atom-12' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='44.3' y='63.7' class='atom-15' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#E84235' >O</text>
<text x='21.4' y='70.8' class='atom-22' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#3B4143' >H</text>
<text x='11.3' y='33.6' class='atom-23' style='font-size:6px;font-style:normal;font-weight:normal;fill-opacity:1;stroke:none;font-family:sans-serif;text-anchor:start;fill:#3B4143' >H</text>
</svg>
 O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 230000000916 dilatatory Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- -1 immunity moderation Substances 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 201000005505 measles Diseases 0.000 description 1
- 230000002175 menstrual Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008125 pain agnosia Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Abstract
本发明公开了一种治疗肝癌的药物。它由下述原料药制成：人参、熟地黄、党参、灵芝、鳖甲、夏枯草、白花蛇舌草、鱼腥草、鸦胆子、蒲黄、半枝莲、黄芪、山豆根、柴胡、丹参、枸杞子、女贞子、墨旱莲、五味子、当归、巴戟天、益母草、茵陈、猪苓、玉竹、赤芍、牡丹皮、山慈菇、僵蚕、鸡血藤、枳实、田基黄、紫草、垂盆草、紫河车和甘草。本发明以上述药物组方，具有舒肝解郁、补肾养阴，消癥散、清热解毒、活血化瘀、化痰利湿、软坚散结、补气养血和滋阴培元的功效，从而有效的治疗肝癌，并可以治愈部分早期肝癌。
Description
技术领域
[0001] 本发明涉及一种治疗肝癌的药物，属于中药技术领域。
背景技术
[0002] 肝癌是临床上最常见的恶性肿瘤之一，根据最新统计，全世界每年新发肝癌患者约六十万，居恶性肿瘤的第五位。肝癌在我国属于高发病，一般男性多于女性。中国是乙肝大国，我国的肝癌多在乙肝肝硬化的基础上发展而来，丙肝病人也在逐渐增加，乙肝后也会发展为肝癌。目前我国发病人数约占全球的半数以上，占全球肝癌病人的55%，已经成为严重威胁我国人民健康和生命的一大杀手，其危险性不容小视。而做好肝癌的早期诊断及治疗对于治疗肝癌非常重要。
[0003] 传统的治疗肝癌的方法是手术切除及放化疗，上述方式对人体的伤害极大。
发明内容
[0004] 本发明克服了上述现有技术的不足，提供了一种治疗肝癌的药物，该药物采用纯然的中药材，对人体基本没有危害，不仅可以有效治疗肝癌，还可以增强患者抵抗力。
[0005] 本发明的技术方案是:一种治疗肝癌的药物，其特征是，由下述重量的原料药制成:人参10g、熟地黄15g、党参10g、灵芝8g、鳖甲15g、夏枯草10g、白花蛇舌草10g、鱼腥草10g、鸦胆子10g、蒲黄10g、半枝莲10g、黄苗10g、山豆根8g、柴胡15g、丹参12g、枸紀子10g、女贞子10g、墨旱莲10g、五味子10g、当归10g、巴戟天8g、益母草10g、茵陈10g、猪苳8g、玉竹10g、赤芍8g、牡丹皮7g、山慈菇10g、僵蚕15g、鸡血藤15g、枳实8g、田基黄10g、紫草10g、垂盆草8g、紫河车8g和甘草5g。
[0006] 制备及服用方法:水煎煮，分两次早晚服用。I个月为I个疗程。
[0007] 各中药的药理作用:
[0008] 人参:甘、微苦，平。归脾、肺、心经。功能与主治:大补元气，复脉固脱，补脾益肺，生津，安神。用于体虚欲脱，肢冷脉微，脾虚食少，肺虚喘咳，津伤口渴，内热消渴，久病虚羸，惊悸失眠，阳瘘宫冷；心力衰竭，心原性休克。
[0009] 熟地黄:甘，微温。归肝、肾经。功能与主治:补血滋阴，益精填髓。用于血虚萎黄，心悸怔忡，月经不调，崩漏下血，肝肾阴虚，腰膝酸软，骨蒸潮热，盗汗遗精，内热消渴，眩晕，耳鸣，须发早白。
[0010] 党参:甘，平。归脾、肺经。健脾益肺，养血生津。用于脾肺气虚，食少倦怠，咳嗽虚喘，气血不足，面色萎黄，心悸气短，津伤口渴，内热消渴。
[0011] 灵芝:甘，平。归心、肺、肝、肾经。具有抗肿瘤及保肝解毒的作用。
[0012] 鳖甲:咸，微寒。归肝、肾经。滋阴潜阳，退热除蒸，软坚散结。用于阴虚发热，骨蒸劳热，阴虚阳尤，头晕目眩，虚风内动。
[0013] 夏枯草:辛、苦，寒。归肝、胆经。功能与主治:清火，明目，散结，消肿。用于目赤肿痛，目珠夜痛，头痛眩晕，瘰疬，瘿瘤，乳痈肿痛；甲状腺肿大，淋巴结结核，乳腺增生，高血压。
[0014] 白花蛇舌草:苦甘，寒。无毒，入心经、肝经、脾经。功效:清热解毒；利湿。主治:肺热喘咳；咽喉肿痛；肠痈；疖肿疮疡；毒蛇咬伤；热淋涩痛；水肿；痢疾；肠炎；湿热黄疸；擅长治疗多种癌症。
[0015] 鱼腥草:清热解毒；排脓消痈；利尿通淋。主治:热淋主肺痈吐脓；痰热喘咳；喉哦；热痢；痈肿疮毒。功效:清热解毒，利尿消肿。治肺炎，疟疾，水肿，淋病，白带，痈肿，痔疮，脱肛，湿瘆，秃疮，疥癣等。
[0016] 鸦胆子:苦，寒；有小毒。归大肠、肝经。功能与主治:清热解毒，截疟，止痢，腐蚀赘疣。用于痢疾，疟疾；外治赘疣，鸡眼。
[0017] 蒲黄:甘，平。归肝、心包经。功能与主治:止血，化瘀，通淋。用于吐血，衄血，咯血，崩漏，外伤出血，经闭痛经，脘腹刺痛，跌扑肿痛，血淋涩痛。
[0018] 半枝莲:辛、苦，寒。归肺、肝、肾经。功能与主治:清热解毒，化瘀利尿。用于疔疮肿毒，咽喉肿痛，毒蛇咬伤，跌扑伤痛，水肿，黄疸
[0019] 黄芪:甘，温。归肺、脾经。功能与主治:补气固表，利尿托毒，排脓，敛疮生肌。用于气虚乏力，食少便溏，中气下陷，久泻脱肛，便血崩漏，表虚自汗，气虚水肿，痈疽难溃，久溃不敛，血虚瘘黄，内热消渴；慢性肾炎蛋白尿，糖尿病。
[0020] 山豆根:苦，寒；有毒。归肺、胃经。清热解毒，消肿利咽。用于火毒蕴结症。
[0021] 柴胡:性微寒，味苦、辛；归肝经、胆经，具疏肝利胆、疏气解郁、散火之功效。
[0022] 丹参:苦，微寒。归心、肝经。功能与主治:活血祛瘀，通经止痛，清心除烦，凉血消痈。用于胸痹心痛，脘腹胁痛，瘕瘕积聚，热痹疼痛，心烦不眠，月经不调，痛经经闭，疮疡肿痛。
[0023] 枸杞子:甘，平。归肝、肾经。滋补肝肾，益精明目。用于虚劳精亏，腰膝酸痛，眩晕耳鸣，阳萎遗精，内热消渴，血虚萎黄，目昏不明。
[0024] 女贞子:甘、苦，凉。归肝、肾经。滋补肝肾，明目乌发。用于肝肾阴虚，眩晕耳鸣，腰膝酸软，须发早白，目暗不明，内热消渴，骨蒸潮热。
[0025] 墨旱莲:甘、酸，寒。归肾、肝经。功能与主治:滋补肝肾，凉血止血。用于肝肾阴虚，牙齿松动，须发早白，眩晕耳呜，腰膝酸软，阴虚血热吐血、衄血、尿血，血痢，崩漏下血，外伤出血。
[0026] 五味子:酸、甘，温。肺、心、肾经。收敛固涩，益气生津，补肾宁心。用于久嗽虚喘，梦遗滑精，遗尿尿频，久泻不止，自汗盗汗，津伤□渴，内热消渴，心悸失眠。
[0027] 当归:甘、辛，温。归肝、心、脾经。补血活血，调经止痛，润肠通便。用于血虚萎黄，眩晕心悸，月经不调，经闭痛经，虚寒腹痛，风湿痹痛，跌扑损伤，痈疽疮疡，肠燥便秘。酒当归活血通经。
[0028] 巴戟天:甘、辛，微温。归肾、肝经。补肾阳，强筋骨，祛风湿。
[0029] 益母草:苦、辛，微寒。归肝、心包、膀胱经。活血调经，利尿消肿，清热解毒。
[0030] 茵陈:苦、辛，微寒。归脾、胃、肝、胆经。清利湿热，利胆退黄。用于黄疸尿少，湿温暑湿，湿疮瘙痒。
[0031] 猪苓:甘、淡，平。归肾、膀胱经。功能与主治:利水渗湿。用于小便不利，水肿，泄湾，淋池，带下。
[0032] 玉竹:甘，微寒。归肺、胃经。功能与主治:养阴润燥，生津止渴。用于肺胃阴伤，燥热咳嗽，咽干口渴，内热消渴。
[0033] 赤芍:苦，微寒。归肝经。清热凉血，散瘀止痛。用于热入营血，温毒发斑，吐血衄血，目赤肿痛，肝郁胁痛，经闭痛经，癥瘕腹痛，跌扑损伤，痈肿疮疡等。
[0034] 牡丹皮:味苦、辛，性微寒，归心、肝、肾经。具有清热凉血、活血散瘀之功。现代研宄表明，牡丹皮有抗炎、镇痛、止血、保肝的作用。
[0035] 山慈菇:甘，微辛，寒。入肝、脾经。消肿，散结，化痰，解毒。治痈疽疔肿，瘰疬，喉痹肿痛，蛇、虫、狂犬伤。
[0036] 僵蚕:祛风定惊，化痰散结。用于惊风抽搐，咽喉肿痛，颁下淋巴结炎，面神经麻痹，皮肤瘙痒。
[0037] 鸡血藤:味苦、微甘，性温，归肝经。具有行血补血、舒筋活络之功。现代研宄表明，鸡血藤有改善造血系统、扩张血管、增加组织血流量、调节免疫、抗血栓、抗肿瘤的作用。
[0038] 枳实:苦、辛、酸，微寒。归脾、胃经。功能与主治:破气消积，化痰散痞。用于积滞内停，痞满胀痛，泻痢后重，大便不通，痰滞气阻，胸痹，结胸，脏器下垂。
[0039]田基黄:为藤黄科植物地耳草的全草。甘；苦；凉。归肺；肝；胃经。具有清热利湿；解毒；散瘀消肿的功能。主湿热黄疸；泄泻；痢疾；肠痈；痈疖肿毒；乳蛾；口疮；目赤肿痛；毒蛇咬伤；跌打损伤。
[0040] 紫草:甘、咸，寒。归心、肝经。功能与主治:凉血，活血，解毒透瘆。用于血热毒盛，斑瘆紫黑，麻瘆不透，疮疡，湿瘆，水火烫伤。
[0041] 垂盆草:甘、淡，凉。归肝、胆、小肠经。利湿退黄，清热解毒。用于湿热黄疽，小便不利，痈肿疮疡。
[0042] 紫河车:甘、咸，温。归心、肺、肾经。功能与主治:温肾补精，益气养血。用于虚劳羸瘦，骨蒸盗汗，咳嗽气喘，食少气短，阳瘘遗精，不孕少乳。
[0043] 甘草:调和诸药。
[0044] 本发明以上述药物组方，具有舒肝解郁、补肾养阴，消癥散、清热解毒、活血化瘀、化痰利湿、软坚散结、补气养血和滋阴培元的功效，从而有效的治疗肝癌，并可以治愈部分早期肝癌。
[0045] 以下结合临床资料及典型病例对本发明的有益效果进一步说明。
[0046] 一、临床观察
[0047] 1、临床资料:选自2009年6月至2011年9月的门诊及住院患者共154例，其中早期肝癌53例。年龄为42-68岁，平均61.5岁。
[0048] 2、诊断标准:以我国卫生部编的《中国常见恶性肿瘤诊治规范》中的原发性肝癌诊断标准为依据。其中，早期肝癌是指单个癌结节最大直径小于3cm或者两个癌结节合计最大直径小于3cm的原发性肝癌。
[0049] 3、治疗方法:服用本发明药物，水煎煮，分两次早晚服用。I个月为I个疗程。
[0050] 4、疗效评定标准:按照卫生部《中国常见恶性肿瘤诊治规范》中原发性肝癌疗效评定标准，以患者治疗前与治疗后B超或CT进行对照比较，以完全缓解(CR)、部分缓解(PR)、稳定(SD )、进展(PD )进彳丁疗效评定。
[0051 ] 5、治疗结果:完全缓解123例，部分缓解14例，稳定17例，进展O例。有效率(CR +PR)为89%，稳定率(CR + PR + SD)为100%。同时早期53例早期肝癌中有41例治愈(月中瘤全部消失，随访I年未复发)。
[0052] 6、毒副作用分析
[0053] 观察的154例患者中，服用本发明中药后仅有2例出现低热、I例轻度腹泻，出现副反应的几率仅为2.0%，经对症处置副反应消失，其余无任何毒副作用。
[0054] 综上所述，本发明用于治疗肝癌的药物，经临床试验，表明其可有效抑制肝癌发展，改善患者症状、体征，且无明显毒副作用。
[0055] 二、典型病例
[0056] 病例1:杨某，女，62岁，患者症状为腹部闷胀，消化不良，有时恶心、呕吐，不明原因的发热，肝区持续性疼痛，确诊为肝癌，经腹部CT检查发现肿瘤大小为2cmX3cm，经服用本发明药物水煎服，每天一剂，分早晚两次服用。服用I个疗程后，患者腹部闷胀、发热、恶心症状明显减轻，食欲增加，经检查肿瘤缩小为IcmX 2cm，病情好转。继续服用5个月，肝区经检查肿瘤消失。随访I年无复发。
[0057] 病例2:张某，男，58岁。患者肝区胀痛不适、食欲下降、消瘦4个月，B超、CT检查发现肿瘤位于右肝后上部，约7X7cm大小。经服用本发明药物水煎服，每天一剂，分早晚两次服用。服用3个疗程后，患者症状减轻，经检查肿瘤缩小为3cmX4cm，病情好转。继续服用6个月，肝区经检查肿瘤小于I X 2cm。
具体实施方式
[0058] 实施例1
[0059] 配方:人参10g、熟地黄15g、党参10g、灵芝8g、鳖甲15g、夏枯草10g、白花蛇舌草10g、鱼腥草10g、鸦胆子10g、蒲黄10g、半枝莲10g、黄苗10g、山豆根8g、柴胡15g、丹参12g、枸f己子10g、女贞子10g、墨旱莲10g、五味子10g、当归10g、巴戟天8g、益母草10g、茵陈10g、猪苓8g、玉竹10g、赤芍8g、牡丹皮7g、山慈菇10g、僵蚕15g、鸡血藤15g、枳实8g、田基黄10g、紫草10g、垂盆草Sg、紫河车Sg和甘草5g。
[0060] 制备及服用方法:水煎煮，分两次早晚服用。I个月为I个疗程。
Claims (1)
1.一种治疗肝癌的药物，其特征是，由下述重量的原料药制成••人参10g、熟地黄15g、党参10g、灵芝8g、鳖甲15g、夏枯草10g、白花蛇舌草10g、鱼腥草10g、鸦胆子10g、蒲黄10g、半枝莲10g、黄苗10g、山豆根8g、柴胡15g、丹参12g、枸紀子10g、女贞子10g、墨旱莲10g、五味子10g、当归10g、巴戟天8g、益母草10g、茵陈10g、猪苳8g、玉竹10g、赤苟8g、牡丹皮7g、山慈葫10g、僵蚕15g、鸡血藤15g、枳实8g、田基黄10g、紫草10g、垂盆草8g、紫河车8g和甘草5g，水煎煮。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310531322.4A CN103550517B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗肝癌的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310531322.4A CN103550517B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗肝癌的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103550517A CN103550517A (zh) | 2014-02-05 |
| CN103550517B true CN103550517B (zh) | 2015-07-29 |
Family
ID=50004989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310531322.4A Expired - Fee Related CN103550517B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗肝癌的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103550517B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977351A (zh) * | 2014-05-23 | 2014-08-13 | 李绍礼 | 一种治疗肝癌的药物组合物 |
| CN104337955A (zh) * | 2014-09-30 | 2015-02-11 | 赵文飞 | 一种治疗肝癌的中药配方及其制备方法 |
| CN104474296A (zh) * | 2014-11-20 | 2015-04-01 | 邹怀亮 | 一种治疗癌症的中药 |
| CN104491737A (zh) * | 2014-12-30 | 2015-04-08 | 潘振奎 | 一种治疗早期肝癌的中药配方 |
| CN105106468A (zh) * | 2015-09-21 | 2015-12-02 | 徐枫 | 一种内科抗肿瘤的中药组合物 |
| CN105582466A (zh) * | 2015-12-31 | 2016-05-18 | 崔鹏 | 一种治疗肝癌早期的中药配方 |
| CN107184822A (zh) * | 2016-03-14 | 2017-09-22 | 陈孝山 | 一种治疗肝癌的中药 |
| CN105797023A (zh) * | 2016-04-11 | 2016-07-27 | 烟台市蓝洋之草医药生物科技有限公司 | 一种中药在制备治疗原发性肝癌的药物中的用途 |
| CN105797024A (zh) * | 2016-04-11 | 2016-07-27 | 烟台市蓝洋之草医药生物科技有限公司 | 一种治疗原发性肝癌的中药 |
| CN111870628B (zh) * | 2020-09-18 | 2021-12-24 | 董克礼 | 治疗慢性乙肝的药物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408404A (zh) * | 2002-07-22 | 2003-04-09 | 周宝义 | 癌扶平 |
| CN1583141A (zh) * | 2004-06-08 | 2005-02-23 | 唐宗园 | 一种治疗恶性肿瘤的中药 |
| CN101670071A (zh) * | 2009-09-25 | 2010-03-17 | 卢速江 | 治疗癌症的中药制剂及其制备方法 |
| CN101773636A (zh) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | 一种抗肿瘤纳米中药及其生产方法 |
| CN102940773A (zh) * | 2012-12-04 | 2013-02-27 | 邓鑫 | 抑制肝癌转移的中药制剂及其制备方法 |
-
2013
- 2013-11-01 CN CN201310531322.4A patent/CN103550517B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1408404A (zh) * | 2002-07-22 | 2003-04-09 | 周宝义 | 癌扶平 |
| CN1583141A (zh) * | 2004-06-08 | 2005-02-23 | 唐宗园 | 一种治疗恶性肿瘤的中药 |
| CN101773636A (zh) * | 2009-01-09 | 2010-07-14 | 苏州知微堂生物科技有限公司 | 一种抗肿瘤纳米中药及其生产方法 |
| CN101670071A (zh) * | 2009-09-25 | 2010-03-17 | 卢速江 | 治疗癌症的中药制剂及其制备方法 |
| CN102940773A (zh) * | 2012-12-04 | 2013-02-27 | 邓鑫 | 抑制肝癌转移的中药制剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103550517A (zh) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103550517B (zh) | 一种治疗肝癌的药物 | |
| CN100417403C (zh) | 治疗癌症的中药 | |
| CN104107318A (zh) | 一种治疗瘀血阻滞型月经不调的中药组合物 | |
| CN103550695B (zh) | 一种治疗乳腺癌的药物 | |
| CN103751570A (zh) | 一种内服治疗偏头痛的中药 | |
| CN104147514A (zh) | 治疗颈椎病的中药组合物及其制备方法 | |
| CN101926961A (zh) | 一种内服治疗盆腔炎的中药组合物 | |
| CN103550696B (zh) | 一种治疗肺癌的药物 | |
| CN106267120A (zh) | 一种治疗鼻炎的中药制剂及其制备方法 | |
| CN103316249B (zh) | 一种芪杉胶囊及其制备工艺 | |
| CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
| CN102988639B (zh) | 一种治疗颈椎病的药物及其制备方法 | |
| CN101204494B (zh) | 一种治疗慢性肠炎的药物 | |
| CN105079549A (zh) | 一种治疗狼疮性肾炎的中药 | |
| CN105435131A (zh) | 一种治疗慢性心衰的中药组合物及其制备方法 | |
| CN102357228A (zh) | 一种治疗肝病的中药组合物 | |
| CN104547553A (zh) | 一种治疗神经性内分泌紊乱的中药 | |
| CN101912502A (zh) | 治疗急性膀胱尿道炎的中药 | |
| CN104383464A (zh) | 一种治疗卵巢癌的中药组合物 | |
| CN104398927A (zh) | 治疗膝关节滑膜炎的中药制剂 | |
| CN104225531A (zh) | 一种治疗冠心病的中药 | |
| CN103610877A (zh) | 一种乳腺癌术后恢复调养的中药组合物 | |
| CN103463375B (zh) | 一种治疗慢性病毒性乙型肝炎的中药组合物 | |
| CN101869629B (zh) | 一种治疗肾结石的中药 | |
| CN105311527A (zh) | 一种用于治疗子宫内膜移位症的中药制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SU LEI Free format text: FORMER OWNER: TIAN JING Effective date: 20150619 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Su Lei Inventor before: Tian Jing Inventor before: Zhang Weicong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: TIAN JING ZHANG WEICONG TO: SU LEI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150619 Address after: No. 1920 people's Hospital of Zhangqiu City, Zhangqiu City, Ji'nan City, Shandong province 250200 Huiquan Road Applicant after: Su Lei Address before: No. 1920 people's Hospital of Zhangqiu City, Zhangqiu City, Ji'nan City, Shandong province 250200 Huiquan Road Applicant before: Tian Jing |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150729 Termination date: 20151101 |
|
| EXPY | Termination of patent right or utility model |